Trial Profile

A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 11 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Entinostat (Primary) ; Exemestane; Goserelin
Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Male breast cancer
Focus Registrational; Therapeutic Use

Most Recent Events

12 Jun 2025 Planned End Date changed from 25 Jun 2025 to 2 Jun 2026.
10 Jul 2024 Planned End Date changed from 14 Jun 2024 to 25 Jun 2025.
15 Aug 2023 Planned End Date changed from 28 Oct 2028 to 14 Jun 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com